Ultrasound-guided percutaneous sclerotherapy versus surgical resection in the treatment of large hepatic hemangiomas: a retrospective study
Open Access
- 7 April 2022
- journal article
- research article
- Published by Springer Nature in BMC Surgery
- Vol. 22 (1) , 1-9
Abstract
Background: It is no consensus on the best management for patients with large hepatic hemangiomas. This study was designed to evaluate the efficacy and safety of percutaneous sclerotherapy compared to surgical resection for large hepatic hemangiomas. Methods: A total of 89 patients with large hepatic hemangiomas from single center underwent either percutaneous sclerotherapy (n = 14) or surgical resection (n = 75) as first-line treatment was retrospectively studied, followed up for 9–24 months using ultrasound. Terms of intraoperative and postoperative information, postoperative complications, and treatment effectiveness were compared between the two groups. Results: Percutaneous sclerotherapy had shorter operative time (p < 0.001), less blood loss, lower rate of prophylactic abdominal drainage (97.3% vs. 0%, p < 0.001), fewer minor complications (48.0% vs. 7.1%, p < 0.01), shorter hospital stay (p < 0.001), lower hospital cost (p < 0.001), higher Alb level (p < 0.001) and lower postoperative clinical index including ALT, AST and WBC (p < 0.001 for both) than did surgical resection. The major complications were demonstrated no significant difference between the two groups. In addition, the mean maximum cross-sectional areas of hemangioma dropped from 5044.1 ± 2058.0 mm2 to 1924.6 ± 1989.5 mm2 (65.2% reduction) during 9–24 months follow-up (p < 0.001) in the percutaneous sclerotherapy group, while all patients in the surgical resection group achieved complete response. Conclusion: Percutaneous sclerotherapy is the preferred method for the treatment of large hepatic hemangioma over surgical resection when compared with the items of postoperative recovery, blood loss, complications, hospital stays, and lower hospital costs. The reduction of the maximum cross-sectional area of hepatic hemangioma in the percutaneous sclerotherapy group is satisfactory.Keywords
This publication has 34 references indexed in Scilit:
- Laparoscopic Radiofrequency Ablation for Large Subcapsular Hepatic Hemangiomas: Technical and Clinical OutcomesPLOS ONE, 2016
- Intralesional Bleomycin Injections for Vascular MalformationsPlastic and Reconstructive Surgery, 2016
- Treatment of tongue cavernous haemangioma with direct puncture and sclerotization with ethanolRadiology and Oncology, 2015
- ACG Clinical Guideline: The Diagnosis and Management of Focal Liver LesionsAmerican Journal of Gastroenterology, 2014
- A clinical study of pingyangmycin sclerotherapy for venous malformation: an evaluation of 281 consecutive patientsJournal of Clinical Pharmacy and Therapeutics, 2014
- Management of Giant Hemangioma of the Liver: Resection versus ObservationJournal of the American College of Surgeons, 2010
- Intralesional injection of Pingyangmycin for vascular malformations in oral and maxillofacial regions: An evaluation of 297 consecutive patientsOral Oncology, 2009
- Sclerosing Therapy as First Line Treatment for Low Flow Vascular Lesions of the OrbitAmerican Journal of Ophthalmology, 2006
- Classification of Surgical ComplicationsAnnals of Surgery, 2004
- Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosisEuropean Journal of Cell Biology, 2001